Projects we are developing

In Immunology

A 10% liquid all-purpose immunoglobulin is currently being developed for European registration. In the portfolio of products being developed by the LFB Group, there is also a monoclonal anti-D, a CD20 and a plasma-derived complement factor H.

In Hemostasis / Rare Diseases

The LFB Group is developing a variety of pharmaceutical projects aiming to improve patients' quality of life, including a concentrated form of Factor VIII that makes it possible to reduce the injection volume by 50% and thus, the duration of administration.

Other current projects include the proposed internationalization of Factor XI and a recombinant activated factor VII, using transgenic production.

In Intensive Care

Extensions of indications for recombinant human antithrombin and Shigamabs® with Thallion in E. coli infections are being developed, as is a project to internationalize our fibrinogen.